1,3-二(2-丙基戊酰基氧基)丙-2-基2-丙基戊酸酯 | 146356-76-5

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 甘油脂
• 中文名称: 1,3-二(2-丙基戊酰基氧基)丙-2-基2-丙基戊酸酯
• 英文名称: Glyceryl trivalproate
• 英文别名: 2,3-bis(2-propylpentanoyloxy)propyl 2-propylpentanoate
• CAS: 146356-76-5
• 化学式: C₂₇H₅₀O₆
• 分子量: 470.7
• InChiKey: GNEIIXKXKQGWGU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  8.5
• 重原子数：
  33
• 可旋转键数：
  23
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.89
• 拓扑面积：
  78.9
• 氢给体数：
  0
• 氢受体数：
  6

文献信息

• Sustained release compositions containing valproic acid
  申请人：YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM

  公开号：EP0442012A1

  公开（公告）日：1991-08-21

  The invention relates to controlled release pharmaceutical compositions. These contain as active ingredient valproic acid, a salt of valproic acid, an ester of valproic acid, Valpromide, or any other pharmaceutically acceptable derivative of valproic acid which upon administration to humans provides a serum level of valproic acid, in combination with an additive which is selected from physiologically acceptable polymeric substances and from native proteins. The active ingredient is usually in the range of from 10 to 80 weight per cent. The novel pharmaceutical compositions are prepared by applying a high pressure to a mixture of the ingredients. They result in a prolonged serum level of the active ingredient.

  本发明涉及控释药物组合物。它们含有作为活性成分的丙戊酸、丙戊酸的盐、丙戊酸的酯、丙戊酸钠或任何其他药学上可接受的丙戊酸衍生物，在给人用药后可提供一定水平的丙戊酸血清，同时还含有一种添加剂，该添加剂选自生理学上可接受的聚合物质和本地蛋白质。活性成分的重量百分比通常在 10%至 80%之间。新型药物组合物是通过对成分混合物施加高压来制备的。它们能延长血清中活性成分的含量。
• Controlled release sodium valproate formulation
  申请人：Podhipleux Nilobon

  公开号：US20050276850A1

  公开（公告）日：2005-12-15

  Disclosed is a controlled release formulation comprising valproic acid, pharmaceutically acceptable salt thereof, amide thereof, or derivative thereof.

  所公开的是一种控释制剂，包含丙戊酸、其药学上可接受的盐、其酰胺或其衍生物。
• Sustained-release drug dosage units
  申请人：ABBOTT LABORATORIES

  公开号：EP0430287B2

  公开（公告）日：2000-07-12
• VALPROIC ACID, DERIVATIVES, ANALOGUES, AND COMPOSITIONS INCLUDING SAME AND METHODS FOR THEIR THERAPEUTIC USE
  申请人：Burkin Dean J.

  公开号：US20120003191A1

  公开（公告）日：2012-01-05

  The present disclosure includes methods and compositions for treating any condition or disorder that benefits from activation of the Akt signaling pathway. These methods and compositions involve the use of valproic acid, derivatives, analogs and compositions including the same for treating muscular disorders, such as muscular dystrophy.
• COMPOSITIONS AND METHODS FOR TREATING OBESITY AND OBESITY-RELATED CONDITIONS
  申请人：THE JOHNS HOPKINS UNIVERSITY

  公开号：US20150250747A1

  公开（公告）日：2015-09-10

  The present invention relates to the field of obesity. More specifically, the present invention provides methods and compositions useful in treating obesity and obesity-associated conditions. In one embodiment, a method for treating obesity in a subject comprises the step of administering an effective amount of valproic acid (VPA) or an analog, derivative or metabolite thereof to the subject.